| Literature DB >> 31761566 |
Xiaoli Sun1, Jason S Seidman2, Peng Zhao3, Ty D Troutman4, Nathanael J Spann2, Xuchu Que3, Fangli Zhou5, Zhongji Liao3, Martina Pasillas2, Xiaohong Yang3, Jason A Magida6, Tatiana Kisseleva7, David A Brenner3, Michael Downes6, Ronald M Evans6, Alan R Saltiel8, Sotirios Tsimikas3, Christopher K Glass4, Joseph L Witztum9.
Abstract
Oxidized phospholipids (OxPLs), which arise due to oxidative stress, are proinflammatory and proatherogenic, but their roles in non-alcoholic steatohepatitis (NASH) are unknown. Here, we show that OxPLs accumulate in human and mouse NASH. Using a transgenic mouse that expresses a functional single-chain variable fragment of E06, a natural antibody that neutralizes OxPLs, we demonstrate the causal role of OxPLs in NASH. Targeting OxPLs in hyperlipidemic Ldlr-/- mice improved multiple aspects of NASH, including steatosis, inflammation, fibrosis, hepatocyte death, and progression to hepatocellular carcinoma. Mechanistically, we found that OxPLs promote ROS accumulation to induce mitochondrial dysfunction in hepatocytes. Neutralizing OxPLs in AMLN-diet-fed Ldlr-/- mice reduced oxidative stress, improved hepatic and adipose-tissue mitochondrial function, and fatty-acid oxidation. These results suggest targeting OxPLs may be an effective therapeutic strategy for NASH.Entities:
Keywords: MnSOD; atherosclerosis; fibrosis; inflammation; mitochondria; natural antibody; nonalcoholic steatohepatitis; oxidative stress; oxidized phospholipids; steatosis
Mesh:
Substances:
Year: 2019 PMID: 31761566 PMCID: PMC7028360 DOI: 10.1016/j.cmet.2019.10.014
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 31.373